Latest Conference Articles

The 3CL protease inhibitor is designed to suppress the replication of SARS-CoV-2, preventing COVID-19 illness, even if a household member is infected.

Data from conference abstracts and presentations indicate that both preexposure prophylaxis methods continue to demonstrate efficacy.

Although the 16-week end point was not met, tezepelumab demonstrated meaningful effects in patients with chronic spontaneous urticaria (CSU) after 32 weeks.

A pilot program integrated oncology pharmacists into prior authorization workflows to streamline and expedite medication approvals.

Subcutaneous infusion reduces treatment times for patients and eases operational burdens for providers.

Policymakers and health care providers call for reforms to improve transparency, pricing, and patient access.

Specialty pharmacists are critical for enhanced management of clinical and logistical aspects of treatment.

Efficacy and tolerability of topical treatments can vary by region, particularly sensitive areas such as the face and neck.

At week 8, significantly more children, adolescents, and adults who applied 1.5% ruxolitinib cream versus vehicle achieved IGA treatment success.

The administration of immunotherapy in adjuvant, neoadjuvant, and perioperative settings offers distinct benefits and challenges in resectable cancers, with recent clinical trials highlighting its potential to improve long-term outcomes and the need for further research into biomarkers and combination strategies.

Nadofaragene firadenovec led to most patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer (NMIBC) experiencing a complete response (CR) at 3 months.

The FDA’s accelerated approval of lifileucel (Amtagvi; Iovance Biotherapeutics) marks a major milestone in immunotherapy for metastatic melanoma, building on decades of research in tumor-infiltrating lymphocyte therapy.

Immunotherapy pioneer James P. Allison, PhD, revolutionized cancer treatment by discovering immune checkpoint blockade, leading to significant advances in survival rates and ongoing efforts to optimize immuno-oncology strategies.

Melody Smith, MD, MS, discusses how microbiome modulation may influence CAR T-cell therapy toxicity and outcomes, highlighting potential future interventions and clinical integration challenges.

The AACR Immunotherapy Conference 2025 will provide pharmacists with the opportunity to engage with cutting-edge cancer immunotherapy research, explore advancements in treatments, such as immune checkpoint inhibitors and CAR T-cell therapy, and connect with key leaders in the field.

Melody Smith, MD, MS, discusses how the intestinal microbiome influences CAR T-cell therapy outcomes, highlighting the negative impact of certain antibiotics and the potential role of dietary interventions in improving treatment efficacy.

Nivolumab demonstrated a sustained disease-free survival benefit over placebo in high-risk muscle-invasive urothelial carcinoma (MIUC).

The data were presented at the 2025 ASCO Genitourinary Cancers Symposium.

C. Brooke Adams, PharmD, BCOP, discusses the evolving diagnostic criteria and management strategies for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR T-cell therapy, highlighting advances in toxicity prevention and treatment selection.

Data from the phase 2 CABRAMET trial suggests the potential of cabozantinib for treatment of brain metastases from renal cell carcinoma (RCC).

Enfortumab vedotin, trastuzumab deruxtecan, and disitamab vedotin were highlighted at the 2025 ASCO Genitourinary Cancers Symposium.

Panelists at the 2025 ASCO Genitourinary Cancers Symposium discussed challenges and new approaches to treatment.

The combination of the antibody-drug conjugate and PD-1/L1 inhibitor yielded an improved progression-free survival in locally advanced or metastatic urothelial carcinoma.

The data were presented at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, California.

The expanding role of real-world evidence in regulatory and health technology assessment (HTA) decision-making highlights its growing acceptance for supplementing clinical trial data, addressing evidence gaps, and informing treatment value, despite challenges in data quality, accessibility, and regulatory compliance.

Andrew Lin, PharmD, BCOP, discusses his pharmacist-led study examining the association between early tacrolimus levels and outcomes post-allogeneic hematopoietic cell transplantation.

The combination greatly improved progression-free survival and overall survival.

Talazoparib in combination with enzalutamide yielded significant improvements in radiographic progression-free survival and overall survival.